AVTXHealthcareSmall-Cap
Avalo Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Avalo Therapeutics, Inc. (AVTX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are AVTX insiders buying or selling?
Avalo Therapeutics, Inc. insiders reported 101 open-market buys ($55.8M) and 18 sells ($9.8M) across 119 Form 4 filings — a net buying position of $46.1M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jul 2, 2026)
Total Form 4 filings
119
SEC EDGAR
Insider filers
20
Insider buys (101)
$55.8M
Insider sells (18)
$9.8M
Insider sentiment
Net buyingNet insider flow of $46.1M in net buying.
Recent AVTX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 2, 2026 | Mittie Doyle | Chief Medical Officer | Sale | 4.7K | $20.00 | $93.1K |
| Jun 25, 2026 | Mittie Doyle | Chief Medical Officer | Sale | 1.4K | $18.00 | $26.1K |
| Jun 1, 2026 | Mittie Doyle | Chief Medical Officer | Sale | 679 | $16.00 | $10.9K |
| May 19, 2026 | Mittie Doyle | Chief Medical Officer | Sale | 3.0K | $18.76 | $56.3K |
| May 11, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Sale | 18.6K | $24.12 | $448.8K |
| May 7, 2026 | Paul Varki | Chief Legal Officer | Sale | 75.1K | $20.17 | $1.5M |
| May 7, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Sale | 47.0K | $20.19 | $948.7K |
| May 7, 2026 | Mittie Doyle | Chief Medical Officer | Sale | 108.2K | $20.61 | $2.2M |
| May 7, 2026 | Mitchell Chan | Director | Sale | 3.2K | $22.88 | $72.5K |
| May 1, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Sale | 16.9K | $13.16 | $222.6K |
| Apr 8, 2026 | Mittie Doyle | Chief Medical Officer | Sale | 4.0K | $18.01 | $71.5K |
| Apr 3, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Sale | 16.0K | $16.96 | $270.6K |
| Apr 3, 2026 | Mittie Doyle | Chief Medical Officer | Sale | 679 | $16.00 | $10.9K |
| Mar 18, 2026 | Mittie Doyle | Chief Medical Officer | Sale | 25.5K | $16.15 | $411.6K |
| Nov 17, 2025 | Jonathan Goldman | Director | Sale | 11.4K | $14.33 | $162.9K |
| Nov 14, 2024 | June Sherie Almenoff | Director | Purchase | 1.0K | $12.75 | $12.7K |
| Jun 28, 2023 | Steven Boyd | 10% Owner | Sale | 3.7M | $0.59 | $2.2M |
| Jun 27, 2023 | Caissa Capital Management ltd. | 10% Owner | Sale | 1.6M | $0.64 | $1.0M |
| Jun 20, 2023 | Caissa Capital Management ltd. | 10% Owner | Purchase | 8.2K | $3.88 | $31.6K |
| Jun 14, 2023 | Caissa Capital Management ltd. | 10% Owner | Purchase | 16.9K | $3.77 | $63.6K |
| Jun 13, 2023 | Christopher Ryan Sullivan | Chief Financial Officer | Purchase | 511 | $3.42 | $1.7K |
| Jun 13, 2023 | Garry Arthur Neil | CEO and Chairman of the Board | Purchase | 4.0K | $3.42 | $13.7K |
| Jun 9, 2023 | Caissa Capital Management ltd. | 10% Owner | Purchase | 14.4K | $3.91 | $56.4K |
| Jun 2, 2023 | Caissa Capital Management ltd. | 10% Owner | Purchase | 844 | $2.87 | $2.4K |
| May 30, 2023 | Caissa Capital Management ltd. | 10% Owner | Purchase | 2.7K | $2.79 | $7.5K |
Showing the 25 most recent of 119 Form 4 filings for Avalo Therapeutics, Inc..
Most active AVTX insiders
- Steven Boyd56 filings
- Caissa Capital Management ltd.14 filings
- Christopher Ryan Sullivan8 filings
- Mittie Doyle8 filings
- James Archie Harrell Jr7 filings
Ask anything about AVTX insider activity
Use Trabud's AI agent to query Avalo Therapeutics, Inc.'s Form 4 history in plain English — "Show me AVTX CEO purchases this year" or compare it against any other ticker.
Open the AI agentAVTX insider trading FAQ
Are Avalo Therapeutics, Inc. insiders buying or selling?
Across 119 SEC Form 4 filings, Avalo Therapeutics, Inc. (AVTX) insiders reported 101 open-market purchases totaling $55.8M and 18 sales totaling $9.8M. That is a net buying position of $46.1M.
How many insiders trade AVTX stock?
20 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Avalo Therapeutics, Inc.. The most recent filing was accepted on Jul 2, 2026.
Where does Trabud get AVTX insider trading data?
All AVTX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.